Tailoring renal-clearable zwitterionic cyclodextrin for colorectal cancer-selective drug delivery

Blanco, E. et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2015).

Article  CAS  Google Scholar 

Yu, M. X. & Zheng, J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano 9, 6655–6674 (2015).

CAS  Google Scholar 

Nurunnabi, M. et al. In vivo biodistribution and toxicology of carboxylated graphene quantum dots. ACS Nano 7, 6858–6867 (2013).

CAS  Google Scholar 

Li, B. & Lane, L. A. Probing the biological obstacles of nanomedicine with gold nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1542 (2019).

Google Scholar 

Zhang, Y. N. et al. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Release 240, 332–348 (2016).

Article  CAS  Google Scholar 

Longmire, M. et al. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3, 703–717 (2008).

Article  CAS  Google Scholar 

Cheng, Y. H. et al. Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach. ACS Nano 14, 3075–3095 (2020).

CAS  Google Scholar 

Lammers, T. Macro-nanomedicine: targeting the big picture. J. Control. Release 294, 372–375 (2019).

Article  CAS  Google Scholar 

Choi, H. S. et al. Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165–1170 (2007).

Article  CAS  Google Scholar 

Liu, J. B. et al. Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Mater. Today 16, 477–486 (2013).

Article  CAS  Google Scholar 

Zhou, C. et al. Luminescent gold nanoparticles with efficient renal clearance. Angew. Chem. Int. Ed. 50, 3168–3172 (2011).

Article  CAS  Google Scholar 

Zhou, C. et al. Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Angew. Chem. Int. Ed. 51, 10118–10122 (2012).

Article  CAS  Google Scholar 

Liu, J. B. et al. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. J. Am. Chem. Soc. 135, 4978–4981 (2013).

Article  CAS  Google Scholar 

Burns, A. A. et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 9, 442–448 (2009).

CAS  Google Scholar 

Ruggiero, A. et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107, 12369–12374 (2010).

Article  CAS  Google Scholar 

Peng, C. Q. et al. Correlating anticancer drug delivery efficiency with vascular permeability of renal clearable versus non-renal clearable nanocarriers. Angew. Chem. Int. Ed. 58, 12076–12080 (2019).

Article  CAS  Google Scholar 

Peng, C. Q. et al. Renal clearable nanocarriers: overcoming the physiological barriers for precise drug delivery and clearance. J. Control. Release 322, 64–80 (2020).

Article  CAS  Google Scholar 

Peng, C. et al. Tuning the in vivo transport of anticancer drugs using renal-clearable gold nanoparticles. Angew. Chem. Int. Ed. 58, 8479–8483 (2019).

Article  CAS  Google Scholar 

Liu, J. et al. PEGylation and zwitterionization: pros and cons in the renal clearance and tumor targeting of near-IR-emitting gold nanoparticles. Angew. Chem. Int. Ed. 52, 12572–12576 (2013).

Article  CAS  Google Scholar 

Kang, H. et al. Renal clearable theranostic nanoplatforms for gastrointestinal stromal tumors. Adv. Mater. 32, e1905899 (2020).

Article  Google Scholar 

Kang, H. et al. Renal clearable organic nanocarriers for bioimaging and drug delivery. Adv. Mater. 28, 8162–8168 (2016).

Article  CAS  Google Scholar 

Wang, H. et al. Renal-clearable porphyrinic metal–organic framework nanodots for enhanced photodynamic therapy. ACS Nano 13, 9206–9217 (2019).

CAS  Google Scholar 

Choi, H. S. et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 5, 42–47 (2010).

Article  CAS  Google Scholar 

Huang, H. et al. Inorganic nanoparticles in clinical trials and translations. Nano Today 35, 100972 (2020).

CAS  Google Scholar 

Missaoui, W. N. et al. Toxicological status of nanoparticles: what we know and what we don’t know. Chem. Biol. Interact. 295, 1–12 (2018).

Article  CAS  Google Scholar 

Kang, H. et al. Size-dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv. Healthc. Mater. 9, 1901223 (2020).

Article  CAS  Google Scholar 

Choi, H. S. et al. Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat. Biotechnol. 31, 148–153 (2013).

Article  CAS  Google Scholar 

Verbeek, F. P. R. et al. Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann. Surg. Oncol. 21, S528–S537 (2014).

Article  Google Scholar 

Sofias, A. M. et al. Tumor targeting by α_vβ₃-integrin-specific lipid nanoparticles occurs via phagocyte hitchhiking. ACS Nano 14, 7832–7846 (2020).

CAS  Google Scholar 

McNeeley, K. M. et al. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 18, 385101 (2007).

Article  Google Scholar 

Shuhendler, A. J. et al. A novel solid lipid nanoparticle formulation for active targeting to tumor α_vβ₃ integrin receptors reveals cyclic RGD as a double-edged sword. Adv. Healthc. Mater. 1, 600–608 (2012).

Article  CAS  Google Scholar 

Cheng, W. W. & Allen, T. M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv. J. Control. Release 126, 50–58 (2008).

Article  CAS  Google Scholar 

Zhang, Y. et al. Strategies and challenges to improve the performance of tumor-associated active targeting. J. Mater. Chem. B 8, 3959–3971 (2020).

Article  CAS  Google Scholar 

Zhao, Z. et al. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).

Article  CAS  Google Scholar 

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 70, 313–313 (2020).

Article  Google Scholar 

McCleary, N. J. et al. Personalizing adjuvant therapy for stage II/III colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book. 37, 232–245 (2017).

Article  Google Scholar 

Jalaeikhoo, H. et al. Effectiveness of adjuvant chemotherapy in patients with stage II colorectal cancer: a multicenter retrospective study. J. Res. Med. Sci. 24, 39 (2019).

Article  CAS  Google Scholar 

Taieb, J. & Gallois, C. Adjuvant chemotherapy for stage III colon cancer. Cancers 12, 2679 (2020).

Article  CAS  Google Scholar 

Braun, M. S. & Seymour, M. T. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther. Adv. Med. Oncol. 3, 43–52 (2011).

Article  CAS  Google Scholar 

Xie, Y. H. et al. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 5, 22 (2020).

Article  CAS  Google Scholar 

Ooi, H. W. et al. Multivalency enables dynamic supramolecular host-guest hydrogel formation. Biomacromolecules 21, 2208–2217 (2020).

Article  CAS  Google Scholar 

Lee, D. W. et al. Supramolecular assembly based on host–guest interaction between beta-cyclodextrin and adamantane for specifically targeted cancer imaging. J. Ind. Eng. Chem. 57, 37–44 (2018).

Article  CAS  Google Scholar 

Galema, H. A. et al. Fluorescence-guided surgery in colorectal cancer; a review on clinical results and future perspectives. Eur. J. Surg. Oncol. 48, 810–821 (2022).

Article  Google Scholar 

Tringale, K. R. et al. Image-guided surgery in cancer: a strategy to reduce incidence of positive surgical margins. Wiley Interdiscip. Rev. Syst. Biol. 10, e1412 (2018).

Google Scholar 

Keller, D. S. et al. Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions. Lancet Gastroenterol. Hepatol. 2, 757 (2017).

Article  Google Scholar 

Shukla, A. et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol. Cancer 9, 314 (2010).

Article  CAS  Google Scholar 

Salaroglio, I. C. et al. ERK is a pivotal player of chemo-immune-resistance in cancer. Int. J. Mol. Sci. 20, 2505 (2019).

Article  CAS  Google Scholar 

Christowitz, C. et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer 19, 757 (2019).

Article  Google Scholar 

Ortiz, R. et al. Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress. Cancers 13, 2058 (2021).

Article  CAS  Google Scholar 

Kim, D. H. et al. Effects of kefir on doxorubicin-induced multidrug resistance in human colorectal cancer cells. J. Funct. Food 78, 104371 (2021).

Article  CAS  Google Scholar 

Yuan, C. et al. Inclusion complex of astaxanthin with hydroxypropyl-beta-cyclodextrin: UV, FTIR, H-1 NMR and molecular modeling studies. Carbohydr. Polym. 89, 492–496 (2012).

Article  CAS  Google Scholar 

Hamdi, H. et al. Spectroscopic studies of inclusion complex of beta-cyclodextrin and benzidine diammonium dipicrate. Spectrochim. Acta A 75, 32–36 (2010).

Article  CAS  Google Scholar 

Lv, S. et al. High drug loading and sub-quantitative loading efficiency of polymeric micelles driven by donor–receptor coordination interactions. J. Am. Chem. Soc. 140, 1235–1238 (2018).

Article  CAS  Google Scholar 

Hiensch, A. E. et al. Doxorubicin-induced skeletal muscle atrophy: elucidating the underlying molecular pathways. Acta Physiol. 229, e13400 (2020).

Article  Google Scholar 

Ou, H. C. et al. Low-level laser prevents doxorubicin-induced skeletal muscle atrophy by modulating AMPK/SIRT1/PCG-1alpha-mediated mitochondrial function, apoptosis and up-regulation of pro-inflammatory responses. Cell Biosci. 11, 200 (2021).

Article  CAS  Google Scholar 

Henriksen, P. A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 104, 971–977 (2018).

Article  CAS  Google Scholar 

Tian, Z. et al. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer 20, 1139 (2020).

Article  CAS  Google Scholar 

Luo, R. et al. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int. J. Pharm. 519, 1–10 (2017).

Article  CAS  Google Scholar 

Patel, K. J. et al. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother. Pharmacol. 72, 127–138 (2013).

Article  CAS  Google Scholar 

Speth, P. A. et al. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15, 15–31 (1988).

Article  CAS  Google Scholar 

Terasaki, T. et al. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J. Pharm. Sci. 73, 1359–1363 (1984).

Article  CAS  Google Scholar 

Tredan, O. et al. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441–1454 (2007).

Article  CAS  Google Scholar 

Torok, S. et al. Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors. Theranostics 7, 400–412 (2017).

Article  CAS  Google Scholar 

Ziemys, A. et al. Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance. J. Control. Release 291, 99–105 (2018).

Article  CAS  Google Scholar 

Cabral, H. et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815–823 (2011).

Article  CAS  Google Scholar 

Zhou, Q. et al. Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy. Nat. Nanotechnol. 14, 799–809 (2019).

Article  CAS  Google Scholar 

Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653–664 (2010).

Article  CAS  Google Scholar 

Waite, C. L. & Roth, C. M. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit. Rev. Biomed. Eng. 40, 21–41 (2012).

Article  Google Scholar 

Sun, D. X. et al. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano 14, 12281–12290 (2020).

CAS  Google Scholar 

Feng, H. Y. et al. Targeted micellar phthalocyanine for lymph node metastasis homing and photothermal therapy in an orthotopic colorectal tumor model. Nanomicro Lett. 13, 145 (2021).

CAS  Google Scholar 

Hackl, C. et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62, 259–271 (2013).

Article  Google Scholar 

Song, W. et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat. Commun. 9, 2237 (2018).

Article  Google Scholar 

Zhu, C. et al. Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle. Biomaterials 161, 144–153 (2018).

Article  CAS  Google Scholar 

Blackman, L. D. et al. An introduction to zwitterionic polymer behavior and applications in solution and at surfaces. Chem. Soc. Rev. 48, 757–770 (2019).

Article  CAS  Google Scholar 

Okamatsu, A. et al. Design and evaluation of folate-appended alpha-, beta-, and gamma-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier in vitro and in vivo. Biomacromolecules 14, 4420–4428 (2013).

Article  CAS  Google Scholar 

Okamatsu, A. et al. Folate-appended beta-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo. Bioconjugate Chem. 24, 724–733 (2013).

Article  CAS  Google Scholar 

Hyun, H. et al. 700-nm zwitterionic near-infrared fluorophores for dual-channel image-guided surgery. Mol. Imaging Biol. 18, 52–61 (2016).

Article  CAS  Google Scholar 

Shao, Q. & Jiang, S. Influence of charged groups on the properties of zwitterionic moieties: a molecular simulation study. J. Phys. Chem. B 118, 7630–7637 (2014).

Article  CAS  Google Scholar 

Dwivedi, R. et al. Design of therapeutically improved analogue of the antimicrobial peptide, indolicidin, using a glycosylation strategy. Amino Acids 51, 1443–1460 (2019).

Article  CAS  Google Scholar 

Xu, X. D. et al. In situ recognition of cell-surface glycans and targeted imaging of cancer cells. Sci. Rep. 3, 2679 (2013).

Article  CAS  Google Scholar 

Kasashima, H. et al. Mouse model of colorectal cancer: orthotopic co-implantation of tumor and stroma cells in cecum and rectum. STAR Protoc. 2, 100297 (2021).

Article  CAS  Google Scholar 

Gontijo, S. M. L. et al. Erlotinib/hydroxypropyl-beta-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation. J. Incl. Phenom. Macrocycl. Chem. 83, 267–279 (2015).

Article  CAS  Google Scholar